Clinical trialNCT04691375TerminatedPhase 1Interventional

A Study of PY314 in Subjects With Advanced Solid Tumors

SponsorIkena OncologyEnrollment86Advanced Solid TumorBreast CancerColorectal CancerGynecologic CancerHormone Receptor/Growth Factor Receptor-Negative Breast CancerLung Adenocarcinoma+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Len Reyno, MD
Ikena Oncology
Study Director
clinicaltrials.gov ↗
Marc Chamberlain, MD
Ikena Oncology
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Scottsdale - Ppds
Phoenix, Arizona, United States
Honor Health Research Institute
Scottsdale, Arizona, United States
City of Hope - Comprehensive Cancer Center
Duarte, California, United States
Stanford Hospital and Clinics
Palo Alto, California, United States
Uc San Diego Moores Cancer Center
San Diego, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Mayo Clinic Jacksonville - Ppds
Jacksonville, Florida, United States
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
University of Chicago
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Mayo Clinic - Ppds
Rochester, Minnesota, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
the Cleveland Clinic Foundation
Cleveland, Ohio, United States
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Ohsu Knight Cancer Institute Beaverton Clinic
Portland, Oregon, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States
Start South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
Next Virginia
Fairfax, Virginia, United States
Wisconsin Institutes for Medical Research
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Combination Therapy: PY314 + PembrolizumabPY314

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Oct 2020
Primary completion: 31 Aug 2023
Completion: 22 Sept 2023
Last update posted: 22 Mar 2024
Registered enrollment: 86
Registry id: NCT04691375

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.